Fig. 1From: The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsThe progression-free survival (PFS) (a) and overall survival (OS) (b) were similar between the patients receiving 30 mg and 40 mg daily of afatinib (median PFS: 469 vs. 443 days, log-rank p = 0.8418; log-rank p = 0.3522 for OS)Back to article page